Steg, Philippe Gabriel2; van 't Hof, Arnoud3; Hamm, Christian W3; Clemmensen, Peter4; Lapostolle, Frédéric3; Coste, Pierre3; Ten Berg, Jurrien3; Van Grunsven, Pierre3; Eggink, Gerrit Jan3; Nibbe, Lutz3; Zeymer, Uwe3; Campo dell' Orto, Marco3; Nef, Holger3; Steinmetz, Jacob5; Soulat, Louis3; Huber, Kurt3; Deliargyris, Efthymios N3; Bernstein, Debra3; Schuette, Diana3; Prats, Jayne3; Clayton, Tim3; Pocock, Stuart3; Hamon, Martial3; Goldstein, Patrick3; Juelsgaard, Palle6
1 Department of Clinical Medicine - Anaesthesiology, Department of Clinical Medicine, Health, Aarhus University2 The authors' affiliations are listed in the Appendix.3 unknown4 Institut for Klinisk Medicin5 Kirurgi og Intern Medicin6 Anæstesiologisk Afdeling, TGH, Faculty of Health Sciences, Aarhus University, Aarhus University
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI). Whether these benefits persist in contemporary practice characterized by prehospital initiation of treatment, optional use of glycoprotein IIb/IIIa inhibitors and novel P2Y12 inhibitors, and radial-artery PCI access use is unknown.
New England Journal of Medicine, 2013, Vol 369, Issue 23, p. 2207-17